

Drug Policy:

Danyelza™ (naxitamab-gqqk)

POLICY NUMBER UM ONC_1419	SUBJECT Danyelza™ (naxitamab-gqqk)		DEPT/PROGRAM UM Dept	PAGE 1 of 4
DATES COMMITTEE REVIEWED 01/13/21, 11/15/21, 12/08/21, 05/11/22, 11/09/22, 11/08/23	APPROVAL DATE November 8, 2023	EFFECTIVE DATE November 27, 2023	COMMITTEE APPROVAL DATES 01/13/21, 11/15/21, 12/08/21, 05/11/22, 11/09/22, 11/08/23	
PRIMARY BUSINESS OWNER: UM		COMMITTEE/BOARD APPROVAL Utilization Management Committee		
NCQA STANDARDS UM 2		ADDITIONAL AREAS OF IMPACT		
CMS REQUIREMENTS	STATE/FEDERAL REQUIREMENTS		APPLICABLE LINES OF BUSINESS Commercial, Exchange, Medicaid	

I. PURPOSE

To define and describe the accepted indications for Danyelza (naxitamab-gqqk) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

New Century Health (NCH) is responsible for processing all medication requests from network ordering providers. Medications not authorized by NCH may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

II. INDICATIONS FOR USE/INCLUSION CRITERIA

A. Continuation requests for a not-approvable medication shall be exempt from this NCH policy provided:

1. The requested medication was used within the last year, **AND**
2. The member has not experienced disease progression and/or no intolerance to the requested medication, **AND**
3. Additional medication(s) are not being added to the continuation request.

B. Neuroblastoma

1. Danyelza (naxitamab-gqqk) will be given in combination with GM-CSF for pediatric members one year of age and older and adult members with relapsed or refractory high-risk neuroblastoma in bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy. High risk neuroblastoma is defined as members who are older than 18 months of age and have disseminated disease, or localized disease with unfavorable markers such as MYCN amplification (*see Attachment A*).

III. EXCLUSION CRITERIA

- A. Disease progression while taking Danyelza (naxitamab-gqgk)
- B. Dosing exceeds single dose limit of Danyelza (naxitamab-gqgk) 3 mg/kg (up to 150 mg/day).
- C. Investigational use of Danyelza (naxitamab-gqgk) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
 - 1. Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
 - 2. Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
 - 3. Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definition of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
 - 4. Whether the experimental design, in light of the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
 - 5. That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
 - 6. That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
 - 7. That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

IV. MEDICATION MANAGEMENT

- A. Please refer to the FDA label/package insert for details regarding these topics.

V. APPROVAL AUTHORITY

- A. Review – Utilization Management Department
- B. Final Approval – Utilization Management Committee

VI. ATTACHMENTS

- A. Attachment A: Children’s Oncology Group Neuroblastoma Risk Strata

VII. REFERENCES

- A. Danyelza prescribing information. Y-mAbs Therapeutics, Inc. New York, NY 2022.
- B. Clinical Pharmacology Elsevier Gold Standard 2023.
- C. Micromedex® Healthcare Series: Thomson Micromedex, Greenwood Village, CO 2023.
- D. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2023.



EmblemHealth®

ConnectiCare

- E. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD 2023.
- F. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014 Apr 20;32(12):1277-80.
- G. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.
- H. Current and Resolved Drug Shortages and Discontinuations Reported to the FDA: <http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm>.
- I. NCQA UM 2023 Standards and Elements.

Attachment A: Children's Oncology Group Neuroblastoma Risk Strata

Children's Oncology Group neuroblastoma risk strata

Risk	Stage	Age	MYCN status	DNA ploidy	INPC	Other
Low*	1	Any	Any	Any	Any	
	2a/2b	Any	Not amp	Any	Any	Resection ≥50 percent
	4s	<365 days	Not amp	DI >1	FH	Asymptomatic
Intermediate†	2a/2b	0-12 years	Not amp	Any	Any	Biopsy or resection <50 percent
	3	<547 days	Not amp	Any	Any	
	3	≥547 days - 12 years	Not amp	Any	FH	
	4	<365 days	Not amp	Any	Any	
	4	365 - <547 days	Not amp	DI >1	FH	
	4s	<365 days	Not amp	Any	Any	Symptomatic
	4s	<365 days	Not amp	DI = 1	Any	Asymptomatic or symptomatic
	4s	<365 days	Not amp	Any	UH	Asymptomatic or symptomatic
High^Δ	2a/2b	Any	Amp	Any	Any	Any degree of resection
	3	Any	Amp	Any	Any	
	3	≥547 days	Not amp	Any	UH	
	4	<365 days	Amp	Any	Any	
	4	365 - <547 days	Amp	Any	Any	
	4	365 - <547 days	Any	DI = 1	Any	
	4	365 - <547 days	Any	Any	UH	
	4s	<365 days	Amp	Any	Any	Asymptomatic or symptomatic

INPC: International Neuroblastoma Pathology Classification; FH: favorable histology; UH: unfavorable histology; Amp: amplified; DI: DNA Index.

* Low risk groups as defined in Children's Oncology Group trial ANBL00B1.

† Intermediate risk group as defined in Children's Oncology Group trial ANBL0531.

Δ High risk group as defined in the Children's Oncology Group trial ANBL0532.

UpToDate®

